Safety and Efficacy of Bone Marrow Derived MNCs for the Treatment of Huntingtons Chorea. It is Self Funded (Patients' Own Funding) Clinical Trial.

Trial Profile

Safety and Efficacy of Bone Marrow Derived MNCs for the Treatment of Huntingtons Chorea. It is Self Funded (Patients' Own Funding) Clinical Trial.

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Bone marrow mononuclear cell therapy (Primary)
  • Indications Huntington's disease
  • Focus Therapeutic Use
  • Acronyms BMACHC
  • Most Recent Events

    • 04 Sep 2014 Planned End Date changed from 1 May 2014 to 1 Jun 2016 as reported by ClinicalTrials.gov record.
    • 04 Sep 2014 Planned primary completion date changed from 1 May 2014 to 1 Jun 2016 as reported by ClinicalTrials.gov record.
    • 29 Apr 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top